The squamous cell carcinoma tumor marker in mammary carcinoma: comparison of polyclonal versus monoclonal antibody-based assays.

@article{citeulike:1476496, abstract = {Pretreatment serum levels of squamous cell carcinoma (SCC)-antigen as determined with a polyclonal and monoclonal antibody-based assay were determined in 136 patients with invasive mammary carcinoma, 8 patients with ductal carcinoma in situ and 23 patients with benign breast diseases. For the polyclonal assay, the overall sensitivity was 44.8\% at a cut-off level of 2.0 ng/ml and 25\% for 2.5 ng/ml. For the monoclonal assay, the sensitivity was 11.0 and 25.0\% at cut-off levels of 2.0 and 1.5 ng/ml, respectively. On the basis of analysis of specificity of the two assays for the benign control group, the cut-off level of the polyclonal assay has to be 2.5 ng/ml in the case of mammary carcinoma, of the monoclonal assay it has to be 2.0 ng/ml. For 175 serum samples of the whole group of patients (pre- and postoperative samples), the polyclonal RIA (x) and the monoclonal IRMA (y) were measured. The orthogonal regression analysis gave the equation: monoclonal IRMA = 1.03 polyclonal RIA - 1.15 ng/ml (Sy.x = 0.48; r = 0.7225). We also came to the conclusion that the SCC-antigen measured by either assay is different.}, address = {Department of General Surgery, University Hospital Nijmegen, The Netherlands.}, author = {Wobbes, T. and Thomas, C. M. and Segers, M. F. }, citeulike-article-id = {1476496}, issn = {0030-2414}, journal = {Oncology}, keywords = {ab, comparison}, number = {1}, pages = {14--18}, posted-at = {2007-07-24 11:17:58}, priority = {2}, title = {The squamous cell carcinoma tumor marker in mammary carcinoma: comparison of polyclonal versus monoclonal antibody-based assays.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/2300380}, volume = {47}, year = {1990} }

TY - JOUR ID - citeulike:1476496 L3 - citeulike-article-id:1476496 TI - The squamous cell carcinoma tumor marker in mammary carcinoma: comparison of polyclonal versus monoclonal antibody-based assays. JF - Oncology VL - 47 IS - 1 SP - 14 EP - 18 AD - Department of General Surgery, University Hospital Nijmegen, The Netherlands. SN - 0030-2414 N2 - Pretreatment serum levels of squamous cell carcinoma (SCC)-antigen as determined with a polyclonal and monoclonal antibody-based assay were determined in 136 patients with invasive mammary carcinoma, 8 patients with ductal carcinoma in situ and 23 patients with benign breast diseases. For the polyclonal assay, the overall sensitivity was 44.8% at a cut-off level of 2.0 ng/ml and 25% for 2.5 ng/ml. For the monoclonal assay, the sensitivity was 11.0 and 25.0% at cut-off levels of 2.0 and 1.5 ng/ml, respectively. On the basis of analysis of specificity of the two assays for the benign control group, the cut-off level of the polyclonal assay has to be 2.5 ng/ml in the case of mammary carcinoma, of the monoclonal assay it has to be 2.0 ng/ml. For 175 serum samples of the whole group of patients (pre- and postoperative samples), the polyclonal RIA (x) and the monoclonal IRMA (y) were measured. The orthogonal regression analysis gave the equation: monoclonal IRMA = 1.03 polyclonal RIA - 1.15 ng/ml (Sy.x = 0.48; r = 0.7225). We also came to the conclusion that the SCC-antigen measured by either assay is different. KW - ab KW - comparison AU - Wobbes, T AU - Thomas, CM AU - Segers, MF PY - 1990/// UR - http://view.ncbi.nlm.nih.gov/pubmed/2300380 ER -